4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported FCF Margin of 2235.81% for Q1 2026, up 33989277.0% year-over-year from N/an in Q1 2025, and down 6624.84% quarter-over-quarter from 34.27% in Q4 2025.
4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of FCF Margin data on file, last reported at 2235.81% in Q1 2026.
- FCF Margin for Q1 2026 came in at 2235.81%, up 33989277.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 146.54% (up 66591433.0% YoY), and the FY2025 annual result was 128.02%, up 36499090.0% from the prior year.
- FCF Margin fell to 2235.81% in Q1 2026 per FDMT's latest filing, from 34.27% in the prior quarter.
- Over five years, FCF Margin peaked at 142505.26% in Q4 2023 and troughed at 4353500.0% in Q4 2024.
- A 5-year average of 394636.08% and a median of 9843.1% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2025: FCF Margin plunged 449600526 bps in 2024, then surged 435353427 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 1832.72% in 2022, then soared by 7876 bps to 142505.26% in 2023, then plunged by 3155 bps to 4353500.0% in 2024, then jumped by 100 bps to 34.27% in 2025, then plunged by 6625 bps to 2235.81% in 2026.
- Business Quant data shows FDMT's FCF Margin at 2235.81% in Q1 2026, 34.27% in Q4 2025, and 51563.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -2,235.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,235.81% |
| Dec 31, 2025 | 34.27% |
| Sep 30, 2025 | -51,563.33% |
| Jun 30, 2025 | -292,893.33% |
| Mar 31, 2025 | -342,128.57% |
| Dec 31, 2024 | -4,353,500.00% |
| Sep 30, 2024 | -1,068,366.67% |
| Jun 30, 2024 | -594,200.00% |
| Mar 31, 2024 | -106,421.43% |
| Dec 31, 2023 | 142,505.26% |
| Sep 30, 2023 | 1.49% |
| Jun 30, 2023 | -9,843.10% |
| Mar 31, 2023 | -9,484.23% |
| Dec 31, 2022 | -1,832.72% |
| Sep 30, 2022 | -4,003.20% |
| Jun 30, 2022 | -12,929.01% |
| Mar 31, 2022 | -1,952.99% |
| Dec 31, 2021 | -24,708.70% |
| Sep 30, 2021 | -1,220.86% |
| Jun 30, 2021 | -109.12% |